Treatment of LFA-1 associated disorders with increasing doses of LFA-1 antagonist
US7364734B2 · kind B2 · utility
0Cited by
3References
10Claims
0Family size
Assignee
Inventors
Key dates
| Filing date | Mar 10, 2005 |
| Grant date | Apr 29, 2008 |
| Priority date | — |
| Expiry date | Mar 10, 2025 |
Classification
- Technology area (CPC C)Chemistry; Metallurgy
- CPC primaryC07K2317/24
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
A method is provided for reducing the occurrence of fever, headache, nausea and/or vomiting associated with administration of a therapeutic compound to a mammal in need thereof, comprising administering to the mammal a first conditioning dose of a non-target cell depleting compound which binds to a cell surface receptor on a target mammalian cell; and administering a second therapeutic dose of the compound, wherein the second dose is higher than the first dose.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.